0001829126-22-014492.txt : 20220719 0001829126-22-014492.hdr.sgml : 20220719 20220719164139 ACCESSION NUMBER: 0001829126-22-014492 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220713 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220719 DATE AS OF CHANGE: 20220719 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Organicell Regenerative Medicine, Inc. CENTRAL INDEX KEY: 0001557376 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS TRANSPORTATION EQUIPMENT [3790] IRS NUMBER: 474180540 STATE OF INCORPORATION: NV FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55008 FILM NUMBER: 221091965 BUSINESS ADDRESS: STREET 1: 4045 SHERIDAN AVENUE STREET 2: SUITE 239 CITY: MIAMI STATE: FL ZIP: 33140 BUSINESS PHONE: 888-963-7881 MAIL ADDRESS: STREET 1: 4045 SHERIDAN AVENUE STREET 2: SUITE 239 CITY: MIAMI STATE: FL ZIP: 33140 FORMER COMPANY: FORMER CONFORMED NAME: Biotech Products Services & Research, Inc. DATE OF NAME CHANGE: 20150917 FORMER COMPANY: FORMER CONFORMED NAME: BESPOKE TRICYCLES INC DATE OF NAME CHANGE: 20120831 8-K 1 organicell_8k.htm 8-K
0001557376 false 0001557376 2022-07-13 2022-07-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): July 13, 2022

 

ORGANICELL REGENERATIVE MEDICINE, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   000-55008   47-4180540
(State or Other Jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification No.)

 

4045 Sheridan Avenue, Suite 239, Miami Beach, Florida   33140
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (888) 963-7881

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class   Trading Symbol   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

 

As used in this Current Report on Form 8-K, and unless otherwise indicated, the terms “the Company,” “Organicell,” “we,” “us” and “our” refer to Organicell Regenerative Medicine, Inc. and its subsidiaries.

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Effective July 13, 2022, the Company entered into (a) a binding letter of intent with Skycrest Holdings, LLC (“Skycrest”) and Greyt Ventures LLC (“Greyt,” and together with Skycrest, the “Skycrest/Greyt Group”) to invest $2,000,000 in the Company through the purchase of 100,000,000 shares of the Company’s common stock (“Shares”) at a price of $0.02 per Share; and (b) effective July 16, 2022, a second binding letter of intent with Beyond 100 FZE, a Dubai company (“Beyond 100,” and together with the Skycrest/Greyt Group, the “Investors”) to invest $2,000,000 in the Company through the purchase of 100,000,000 Shares at a price of $0.02 per Share.

 

Pursuant to the binding letters of intent (the “LOIs”), the Company has agreed to (a) make certain corporate governance changes as more fully described therein, including allowing the Investors to appoint new independent directors who will comprise a majority of the members of the Board; (b) enter into 36-month consulting agreements with each of Skycrest and Greyt (each, a “Consulting Agreement,” and collectively, the “Consulting Agreements”), pursuant to which (i) Skycrest and Greyt will provide certain advisory services to the Company as more fully set forth in the LOIs; and (ii) Skycrest and Greyt shall each be compensated for their services by the Company issuing to each of them ten year-warrants to purchase 150,000,000 Shares at an exercise price of $0.02 per Share (the “Warrants”), which Warrants will be exercisable on a “cashless” basis; (c) implement certain changes in management, including Albert Mitrani stepping down as Chief Executive Officer; and (d) make modifications to management compensation, all as more fully set forth in the LOIs.

 

Contemporaneously with entering into the respective LOIs, the Skycrest/Greyt Group and Beyond 100 each advanced Organicell $300,000 (a total of $600,000) as good faith deposits against the $2,000,000 (a total of $4,000,000) purchase price for the Shares. Consummation of the transaction is subject to drafting and executing definitive transaction documentation, waiver of the right of first refusal or participation held by Organicell’s existing lender, approval of our board of directors and the satisfaction of other customary closing conditions.

 

It is anticipated that the transactions contemplated by the LOIs will be consummated on or before August 30, 2022 (subject to extension by the parties). In the event the transactions contemplated by the LOIs do not close by such date (unless extended by the parties) as a result of the Company’s failure to satisfy the conditions set forth above, Organicell shall be required to refund the good faith deposit made by and issue 100,000,000 Shares to the Skycrest/Grey Group as a break-up fee and offer Beyond 100 the option to either receive its advance or apply it to the purchase of Shares at a price of $0.015 per Share . In the event the Investors do not consummate the transaction, except as set forth in the previous sentence, the Company will be entitled to specific performance of the purchase and sale of the Shares without having to comply with the other agreements set forth in the LOIs.

 

The above description of the LOIs and the transactions contemplated thereby is qualified in its entirety by reference to the LOIs, which are filed herewith as Exhibits 10.1 and 10.2.

 

The offer and sale of the Shares and Warrants pursuant to the LOIs was made in a private transaction exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), in reliance on exemptions afforded by Section 4(a)(2) of the Securities Act and the rules and regulations promulgated thereunder.

 

1

 

 

Item 3.02 Unregistered Sales of Equity Securities

 

The information set forth under Item 1.01 is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
10.1   Binding Letter of Intent with Skycrest Holdings, LLC and Greyt Ventures LLC
     
10.2   Binding Letter of Intent with Beyond 100 FZE

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: July 19, 2022 ORGANICELL REGENERATIVE MEDICINE, INC.
   
  By: /s/ Ian Bothwell
    Ian Bothwell
Chief Financial Officer

 

3

 EX-10.1 2 organicell_ex10-1.htm EXHIBIT 10.1

 

Exhibit 10.1

 

July 13, 2022

 

Organicell Regenerative Medicine, Inc.

c/o Mr. Albert Mitrani

4045 Sheridan Avenue

Suite 239

Miami, FL 33140

 

RE:BINDING LETTER OF INTENT (“LOI”) FOR THE PURCHASE OF ORGANICELL STOCK

 

This letter of intent (this “LOI”), when signed where indicated below, shall constitute a binding statement to consummate a transaction by and between Organicell Regenerative Medicine, Inc., a Nevada corporation (“Organicell”) and Skycrest Holdings, LLC (“Skycrest”) and Greyt Ventures LLC (“Greyt”), their participants and/or assigns (collectively Skycrest and Greyt are referred to as “Investors”). Organicell and Investors are each referred to herein individually, as a “Party” and collectively, as the “Parties.”

 

The transaction (“Proposed Transaction”) contemplates the following:

 

(i)the purchase by Investors of a limited amount of common stock of Organicell, and

 

(ii)agreement for Investor to provide consulting services to Organicell, and

 

(iii)the agreement of Organicell to make agreed upon management changes and implementation of corporate governance policies, board of director changes and procedures.

 

The Parties desire to enter into the Transaction on the following terms:

 

1.LIMITED STOCK PURCHASE:Investor agrees to purchase $2,000,000 of shares of Organicell restricted common stock (“Shares”) at a purchase price of $0.02 per share, which shall be used by Organicell for Organicell working capital needs (100,000,000 shares). Said shares will be registered and unrestricted concurrent with the filing of the S-1 by BOD.

 

2. CONSULTING AGREEMENTOrganicell and Investor shall enter into a consulting agreement (“Consulting Agreement”) whereby each Skycrest and Greyt shall be retained for 36 months, using their best efforts to provide certain advisory services to Organicell, including:

 

a.Transactions involving relationships and companies that will help develop and expand Organicell’s PPX business (marketing, processing (Quest), and/or sales (telemedicine companies),

 

b.Investment advisory services in connection with future financings that may be required by Organicell.

 

1

 

 

The term of the Consulting Agreement shall be for 36 months. Each Skycrest and Greyt shall receive compensation, issued in full at closing cashless warrants to purchase up to an aggregate of 150,000,000 shares of common stock, each, of Organicell (“Warrants”) generally described below (total 300,000,000 shares):

 

1.Warrants will have a term of ten (10) years in which to exercise;

 

2.Strike Price –$0.02 per share;

 

The Company will file an S-1 registration statement in the future to register the shares underlying the aforementioned Warrants and shares as determined by the BOD.

 

3.CORPORATE GOVERANCE:As an inducement for Investors to enter into this LOI, Organicell agrees to timely implement the following corporate governance and other “best practices” procedures, policies and controls during the first 30 days from the Effective Date:

 

A.Al Mitrani shall agree to step down as CEO of Organicell. Mr. Mitrani will assume the role as Executive Vice President of Sales and be a member of the Board.

 

B.Restructuring of the current BOD where by investors will have majority control which shall also include adding new “independent” BOD members, including an “audit committee financial expert,” and other members with compatible finance, scientific, biotech and marketing and sales experience

 

C.Establish audit, compensation and corporate governance committees comprised of independent directors

 

D.All cash will be managed and controlled through designated bank accounts controlled by Organicell’s CFO and newly appointed CEO, and/or acting CEO, initially Matt Sinnreich (one account for investment proceeds and receipts and another account for expenses), separate and exclusive of all current accounts.

 

E.The parties agree to the attached Exhibit A - Projected operating budget

 

F.Waiver by all current C-Level executives of any compensation that would be due in connection with a change in control and termination of any current rights in their respective agreements to increases in Base Salary, commissions, and fixed bonuses, and other benefits. George Shapiro’s compensation with respect to his consulting agreement shall be terminated with no further obligation related thereto. Accrued salaries, upon review and acceptance, shall be compensated in the form of cashless warrants, on the same terms as set forth above.

 

2

 

 

G.Implementation of policies and procedures to strengthen internal controls with respect to:

 

●Cash Management

 

●Issuance of Corporate Credit Card(s)

 

●Review and approval, and/or renegotiation of agreements and transactions with related parties

 

●Financial reporting

 

●Human Resources

 

H.The annual salaries of Albert Mitrani and Mari Mitrani shall be set at $300,000 each. Any other benefits shall be in line with the Company’s benefits awarded to C-Level employees approved by the new BOD.

 

4.CONDITIONS TO CLOSING:The following shall be conditions precedent to the Closing the Transaction described herein (note: the ADVANCE is to be funded as provided for below and not contingent on a Closing):

 

a.Legal opinion from Organicell’s SEC counsel regarding compliance of the Proposed Transaction,

 

b.Requisite BOD approvals and consents, as a precondition to the funding of the $300,000 by July 15, 2022.

 

c.Execution of definitive agreements for the Organicell Stock Purchase, Consulting Agreement and Warrant Agreement (“Definitive Agreements”),

 

d.Waiver or participation from Organicell’s existing lender (AJB Capital) as to their right to participate in Proposed Transaction.

 

e.In the event any of the above stated four conditions are not met, Organicell must return the $300,000 funded pursuant to this Binding LOI within 30 days from the effective date herein, and, immediately provide Investors with an additional One Hundred Million shares, along with the One Hundred Million shares earned with the $300,000 funding of July 15, 2002, as a Breakup Fee for its’ failure to Close on the full transaction as contemplated within this Binding LOI. If the Investors do not perform or cannot close, they will still be required to pay the Company $2.0 Million in exchange for each of Skycrest and Greyt receiving 100 Million shares of common stock.

 

5.GOOD FAITH:The Parties have agreed to cooperate and exercise their respective commercially reasonable best efforts in good faith, to draft and execute the Definitive Agreements consistent with the terms of this LOI as promptly as reasonably practicable, but in no event, later than August 30, 2022, otherwise, the Breakup Fee, as set forth in paragraph 4e, above, shall go into effect and the refund and issuance of stock shall, pursuant to said Breakup Fee shall be due on August 31, 2022, unless an extension, in writing, is agreed to by all Parties hereto.

 

3

 

 

6.CLOSING:Investors will fund the ADVANCE of $300,000 no later than Friday July 15, 2022. The parties anticipate the closing of the transactions contemplated herein (“Effective Date”), including preparation, negotiation and execution of the Definitive Agreements shall occur within 45 days from the signing of this LOI. No additional funding shall occur until this Transaction is Closed.

 

7.EXPENSES:Each Party to the LOI contemplated hereby shall bear its own legal, accounting and other fees and expenses incurred in connection with the LOI, whether or not the Definitive Agreements are executed, other than the Breakup Fee as stated and described, above.

 

8.BINDING EFFECT:This LOI is intended to constitute a binding agreement among the Parties.

 

9.ADVANCE:As an inducement for Organicell to enter into this LOI, Investors agrees to advance at the time this LOI is executed in the amount of $300,000 (“Advance”). The Advance shall be applied towards the purchase price for the Shares.

 

10. GOVERNING LAW & VENUE:This LOI shall be deemed to be made in and in all respects shall be interpreted, construed and governed by and in accordance with the laws of the State of Florida without regard to the conflicts of law provisions thereof to the extent that such principles would direct a matter to another jurisdiction. The Parties hereto agree that the only Venue for any disputes arising under this LOI or subsequent definitive agreements, shall be Broward County, Florida.

 

11.TERM AND TERMINATION:The Parties have agreed to use their best efforts to consummate the Proposed Transaction within 45 days from execution of this LOI. The LOI may be extended for additional periods upon mutual agreement of the Parties.

 

12.COUNTERPARTS:This LOI may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one agreement. Photocopies, facsimile transmissions, or email transmissions of Adobe portable document format files (also known as “PDF” files) of signatures shall be deemed original signatures and shall be fully binding on the Parties to the same extent as original signatures.

 

4

 

 

13.KEY CONTACTS:Organicell:

 

Albert Mitrani

Albert@organicell.com

Tel:      760 709 2510

 

Ian Bothwell

ian@organicell.com

Tel:      310 200 9741

 

14.PUBLIC DISCLOSURE:Without the prior written consent of the other Parties, and unless required by law, rule or regulation or policy of any national securities exchange or similar regulatory body, the Parties shall not make any public disclosure (orally or in writing) prior to the Closing regarding (i) the existence or terms of this LOI; or (ii) identity of the Parties. If a Party is required by law to make such a disclosure, it will provide the other Parties with prompt written notice prior to making such disclosure.

 

15.AMENDMENTS; WAIVERS:This LOI may not be modified, amended or supplemented except by a written instrument signed by the Parties.

 

16.HEADINGS:Section and other headings contained in this LOI are for reference purposes only and are not intended to describe, interpret, define, or limit the scope, extent, or intent of this LOI or any provision hereof.

 

17.CONFIDENTIALITYTHE PARTIES SHALL CONTINUE TO BOUND BY THE TERMS OF THE PRIOR NDA EXECUTED BETWEEN THE PARTIES

 

SIGNATURE PAGE FOLLOWS

 

5

 

 

ORGANICELL REGENERATIVE MEDICINE, INC,

a Nevada corporation

 

By: /s/ Albert Mitrani  
Name: Albert Mitrani  
Title: CEO  
Date: July 13, 2022  
     
By: /s/ Mari Mitrani  
Name: Mari Mitrani  
Title:    
Date: July 13, 2022  
     
By: /s/ Ian Bothwell  
Name: Ian Bothwell  
Title: CFO  
Date: July 13, 2022  

 

SKYCREST HOLDINGS LLC

a Florida limited liability company

     
By: /s/ Harvey Birdman  
Name: Harvey Birdman  
Title:    
Date: July 13, 2022  

 

GREYT VENTURES LLC

a Delaware limited liability company

 

By:

/s/ Wendy Grey

  
Name:

Wendy Grey

  
Title:    
Date: July 13, 2022  

 

6

 EX-10.2 3 organicell_ex10-2.htm EXHIBIT 10.2

 

Exhibit 10.2

 

July 16, 2022

 

Organicell Regenerative Medicine, Inc.

c/o Mr. Albert Mitrani

4045 Sheridan Avenue

Suite 239

Miami, FL 33140

 

RE:BINDING LETTER OF INTENT (“LOI”) FOR THE PURCHASE OF ORGANICELL STOCK

 

This letter of intent (this “LOI”), when signed where indicated below, shall constitute a binding statement to consummate a transaction by and between Organicell Regenerative Medicine, Inc., a Nevada corporation (“Organicell”) and Beyond 100 FZE, a company incorporated in Dubai (“Beyond”) or any of its affiliate entities (“Investor”). Organicell and Investor are each referred to herein individually, as a “Party” and collectively, as the “Parties.”

 

The transaction (“Transaction”) contemplates the following:

 

(i)the purchase by Investors of a limited amount of common stock of Organicell, and

 

(ii)the agreement of Organicell to make agreed upon management changes and implementation of corporate governance policies, board of director (“BOD”) changes and procedures.

 

The Parties desire to enter into the Transaction on the following terms:

 

1.LIMITED STOCK PURCHASE:Investor agrees to purchase $2,000,000 of shares of Organicell restricted common stock (“Shares”) at a purchase price of $0.02 per share, which shall be used by Organicell for Organicell working capital needs (100,000,000 shares). Said shares will be registered and subsequently unrestricted concurrent with the filing of the S-1 by BOD.

 

2.

CORPORATE GOVERANCE:

As an inducement for Investors to enter into this LOI, Organicell agrees to timely implement the following corporate governance and other “best practices” procedures, policies and controls during the first 30 days from the Effective Date:

 

A.Al Mitrani shall agree to step down as CEO of Organicell. Mr. Mitrani will assume the role as Executive Vice President of Sales and be a member of the Board.

 

B.Restructuring of the current BOD whereby new investors will have majority control which shall also include adding new “independent” BOD members, including an “audit committee financial expert,” and other members with compatible finance, scientific, biotech and marketing and sales experience. Dr Bhupendra Kumar Modi (“Dr. Modi”) shall be appointed to the BOD and serve as Chairman of the Board. The Company shall appoint Gurvinder Pal Singh to serve on the BOD.

 

1

 

 

C.Establish audit, compensation and corporate governance committees comprised of independent directors.

 

D.All cash will be managed and controlled through designated bank accounts controlled by Organicell’s CFO and newly appointed CEO, and/or acting CEO, initially Matt Sinnreich (one account for investment proceeds and receipts and another account for expenses), separate and exclusive of all current accounts.

 

E.The parties agree to the attached Exhibit A - Projected operating budget.

 

F.Waiver by all current C-Level executives of any compensation that would be due in connection with a change in control and termination of any current rights in their respective agreements to increases in Base Salary, commissions, and fixed bonuses, and other benefits. George Shapiro’s compensation with respect to his consulting agreement shall be terminated with no further obligation related thereto. Accrued salaries, upon review and acceptance, shall be compensated in the form of cashless warrants, on the same terms as set forth above.

 

G.Implementation of policies and procedures to strengthen internal controls with respect to:

 

●Cash Management

 

●Issuance of Corporate Credit Card(s)

 

●Review and approval, and/or renegotiation of agreements and transactions with related parties
   
●Financial reporting (including providing periodic financial reports to the BOD as requested by the BOD)
   
●Human Resources

 

H.The annual salaries of Albert Mitrani and Mari Mitrani shall be set at $300,000 each. Any other benefits shall be in line with the Company’s benefits awarded to C-Level employees approved by the new BOD.

 

3.REPRESENTATIONInvestor (and any designated BOD member of Investor) and none of its members, shareholders, managers, directors, officers or affiliates is a “bad actor” as defined under Regulation D.

 

4.GOOD FAITH:The Parties have agreed to cooperate and exercise their respective commercially reasonable best efforts in good faith to draft and execute the Definitive Agreements consistent with the terms of this LOI as promptly as reasonably practicable, but in no event, later than August 30, 2022.

 

5.EXPENSES:Each Party to the LOI contemplated hereby shall bear its own legal, accounting and other fees and expenses incurred in connection with the LOI, whether or not the Definitive Agreements are executed.

 

2

 

 

6.ADVANCE:As an inducement for Organicell to enter into this LOI, Investor agrees to advance the amount of $300,000 (“Advance”) upon execution of this LOI. The Advance shall be wired to the Company’s designated bank account by Tuesday July 18, 2022 (expected to take up to 2-3 days to clear into the Company’s US designated bank account) and applied towards the purchase price for the Shares upon close of the Transaction.

 

In the event the Transaction does not close due to the Company, then Investor shall be entitled to receive reimbursement of the Advance within 30 days or the Investor may elect to convert the Advance into common stock of the Company at price of $0.015 per share. In the event the Transaction does not close due to the Investor, then the Advance shall convert into common stock of the Company at price of $0.02 per share.

 

7.BINDING EFFECT:This LOI is intended to constitute a binding agreement among the Parties.

 

8.ROFR:The Company agrees that Dr. Modi and/or his designated affiliates shall have a right of first refusal (“ROFR”) in connection with the Company’s intentions to enter into any exclusive arrangement providing for manufacturing, distribution, licensing, and commercialization for existing and future products and services to be manufactured, licensed and/or distributed by Organicell or any of its subsidiary entities in India. This ROFR shall expire 18 months from the Closing of the Transaction.

 

9.GOVERNING LAW & VENUE:This LOI shall be deemed to be made in and in all respects shall be interpreted, construed and governed by and in accordance with the laws of the State of Florida without regard to the conflicts of law provisions thereof to the extent that such principles would direct a matter to another jurisdiction. The Parties hereto agree that the only Venue for any disputes arising under this LOI or subsequent definitive agreements, shall be Broward County, Florida.

 

10.COUNTERPARTS:This LOI may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one agreement. Photocopies, facsimile transmissions, or email transmissions of Adobe portable document format files (also known as “PDF” files) of signatures shall be deemed original signatures and shall be fully binding on the Parties to the same extent as original signatures.

 

3

 

 

11.KEY CONTACTS:Organicell:

 

Albert Mitrani

Albert@organicell.com

Tel:       760 709 2510

 

Ian Bothwell

ian@organicell.com

Tel:       310 200 9741

 

12.PUBLIC DISCLOSURE:Without the prior written consent of the other Parties, and unless required by law, rule or regulation or policy of any national securities exchange or similar regulatory body, the Parties shall not make any public disclosure (orally or in writing) prior to the Closing regarding (i) the existence or terms of this LOI; or (ii) identity of the Parties. If a Party is required by law to make such a disclosure, it will provide the other Parties with prompt written notice prior to making such disclosure.

 

13.AMENDMENTS; WAIVERS:This LOI may not be modified, amended or supplemented except by a written instrument signed by the Parties.

 

14.HEADINGS:Section and other headings contained in this LOI are for reference purposes only and are not intended to describe, interpret, define, or limit the scope, extent, or intent of this LOI or any provision hereof.

 

15.CONFIDENTIALITYTHE PARTIES SHALL CONTINUE TO BOUND BY THE TERMS OF THE PRIOR NDA EXECUTED BETWEEN THE PARTIES

  

SIGNATURE PAGE FOLLOWS

 

4

 

 

ORGANICELL REGENERATIVE MEDICINE, INC,

a Nevada corporation

  

By:/s/ Ian Bothwell 
Name:Ian Bothwell
Title:Chief Financial Officer

 

INVESTOR

 

BEYOND 100 FZE

 

By:/s/ Gurvinder Pal Singh 
Name:Gurvinder Pal Singh 
Title:Authorized Signatory 
   
Date:16 July 2022

  

5

 

 EX-101.SCH 4 bpsr-20220713.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 bpsr-20220713_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 bpsr-20220713_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Jul. 13, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 13, 2022
Entity File Number 000-55008
Entity Registrant Name ORGANICELL REGENERATIVE MEDICINE, INC.
Entity Central Index Key 0001557376
Entity Tax Identification Number 47-4180540
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 4045 Sheridan Avenue
Entity Address, Address Line Two Suite 239
Entity Address, City or Town Miami Beach
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33140
City Area Code (888)
Local Phone Number 963-7881
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
XML 8 organicell_8k_htm.xml IDEA: XBRL DOCUMENT 0001557376 2022-07-13 2022-07-13 iso4217:USD shares iso4217:USD shares 0001557376 false 8-K 2022-07-13 ORGANICELL REGENERATIVE MEDICINE, INC. NV 000-55008 47-4180540 4045 Sheridan Avenue Suite 239 Miami Beach FL 33140 (888) 963-7881 false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://organicell.com/role/Cover Cover Cover 1 false false All Reports Book All Reports organicell_8k.htm bpsr-20220713.xsd bpsr-20220713_lab.xml bpsr-20220713_pre.xml organicell_ex10-1.htm organicell_ex10-2.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "organicell_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "organicell_8k.htm" ] }, "labelLink": { "local": [ "bpsr-20220713_lab.xml" ] }, "presentationLink": { "local": [ "bpsr-20220713_pre.xml" ] }, "schema": { "local": [ "bpsr-20220713.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bpsr", "nsuri": "http://organicell.com/20220713", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "organicell_8k.htm", "contextRef": "From2022-07-13to2022-07-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://organicell.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "organicell_8k.htm", "contextRef": "From2022-07-13to2022-07-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001829126-22-014492-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001829126-22-014492-xbrl.zip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end